CGIP19127 / A021602 / Aram Hezel
Research Question:
How well does cabozantinib S-malate work compared with placebo in treating patients
with neuroendocrine tumors that have spread after previous treatment with everolimus?
Basic Study Information
Purpose:
This phase III trial studies cabozantinib to see how well it works compared with placebo
in treating patients with neuroendocrine or carcinoid tumors that may have spread
from where it first started to nearby tissue, lymph nodes, or distant parts of the
body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor,
and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor
growth.
Location: University of Rochester Medical Center
Study Reference #: CGIP19127
Lead Researcher (Principal Investigator)
Lead Researcher:
Aram Hezel
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search